Labiotech.eu

News and Trends 5 Apr 2016

Interviewing one of the Leading Biotech Investors in Scandinavia

The Karolinska Institute (Sweden) is worldwide famous for giving the Nobel Prize every year… It’s also home of Karolinska Development, an investment company span out from Karolinska Institute. I had the chance to meet with Viktor Drvota, its Chief Investment Officer at BIO-Europe Spring 2016 in Stockholm. We had a chance to talk about the […]

April 5, 2016 - 1 minutemin - By Philip Hemme

samsung bioepis biotech rheumatoid arthritis biosimilar flixabi sb4

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi, a biosimilar of Janssen’s blockbuster Remicade for Inflammatory diseases. Samsung Bioepis is a joint venture between Biogen and Samsung BioLogics, a branch of the Korean giant that provides manufacturing services for development of biologicals. It started developing […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Apr 2016

Israeli Cancer Startup catches Investment from 3 major Big Pharma

Metabomed is developing new highly-selective drugs that target cancer metabolism – and it has now raised €15.8M in a series A round and gotten a new CEO from Merck’s ranks. Metabomed was co-founded by MS Ventures (the VC arm of Merck KGaA) and leading researchers in the field of cancer metabolism and computational biology back in 2014. I must […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

perkin elmer chemagic dna extraction blood ngs

News and Trends 5 Apr 2016

How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis?

The increasing relevance of Next Generation Sequencing (NGS) in genetic research means there is a high demand for nucleic acid isolation from human fluids. So how can we perform efficient DNA extraction from human blood? NGS has revolutionised genetic research, by serving as a powerful processing technology, cutting time taken to run genetic analysis and also the cost. […]

April 5, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Apr 2016

Allergy Immunotherapy from Switzerland gets several Million in funding

Anergis (Switzerland) has gotten €4.5M from investors and is planning a phase IIb trial for ATIBAR, its leading candidate to treat Tree allergies. Anergis is developing ultra-fast immunotherapies for allergies, which could be an interesting alternative to current treatments, known as ‘desensitization’ or conventional Allergy Immunotherapy (AIT). This process of inducing tolerance to the allergen requires 3-5 […]

April 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 4 Apr 2016

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

BIO-Europe Spring 2016 is starting off right away with the plenary opening session. The conference was about partnering, trends and opinion from both Biotechs and Pharma… This was the list of pretty impressive speakers: How are Big Pharma positioning themselves in 2016? J&J clearly wants to open up more to the outside of the organisation, […]

April 4, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 3 Apr 2016

What happened this week? CRISPR Crew, SynBio Infograph, Novartis Venture Fund

1. Infographic: A Handy Guide to the European Synthetic Biology Startup Scene 2. Interviewing the Managing Director of the $750M Venture Fund of Novartis 3. The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection 4. UK Cannabis Drug in Phase III Trial Success for Rare Epilepsy 5. From Anti-Ageing Creams to Alzheimer’s, this Biotech ‘Milks’ Tropical Plants […]

April 3, 2016 - 1 minutemin - By Philip Hemme

bioart joana ricou multitudes microbiome

News and Trends 2 Apr 2016

BioArt: Joana Ricou shows the Beautiful Similarities of the Microbiome

Joana Ricou has been dwelling on the frontier of biology and science since she enrolled an Art&Biology programme at Carnegie Mellon (US). Her BioArt works explore the perception of our bodies and the multitudes inside each of us – with a rather scientific approach. We have covered a small part of Ricou’s on our event […]

April 2, 2016 - 4 minutesmins - By Denise Neves Gameiro

biomoti oncojan physiomics virtual tumor

News and Trends 1 Apr 2016

When Nanoparticles meet Virtual Tumours to build Oncology Platform

BioMoti is enhancing cancer treatments via drug delivery innovation and it was one of the companies we visited during Labiotech Tour UK. Its Oncojan platform has caught the eye of Physiomics, a computational system biology Biotech listed on the London Stock Exchange. Oxford-based Physiomics develops computational models of cancer, allowing to simulate the effect of […]

April 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Apr 2016

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based. City: Milan (Italy) Founded: 1996 Employees: (+/-) 120 (as of 12/2015) […]

April 1, 2016 - 1 minutemin - By Joachim Eeckhout

genfit primary billiary cholangitis elafibranor

News and Trends 31 Mar 2016

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease – Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs. Genfit from Lille (France) has been in the spotlight because of its phase III candidate for NASH – something we discussed with its CEO, Jean-François Mouney. Apparently, all the […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

affimed afmd 2015 results immuno oncology

News and Trends 31 Mar 2016

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Affimed from Heidelberg had a ‘formative year’ (hmm) in 2015. Major highlights include raising of €52.6M, expanding to the US and advances in the development of its next-generation antibodies for immuno-oncology. Affimed is a Biopharma focused on discovering and developing highly targeted cancer immunotherapies. It is also one of our trendiest NASDAQ-listed European Biotechs (and the only one […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Interviewing one of the Leading Biotech Investors in Scandinavia

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Israeli Cancer Startup catches Investment from 3 major Big Pharma

How can we Optimise DNA Extraction from Human Blood for more Sensitive NGS Analysis?

Allergy Immunotherapy from Switzerland gets several Million in funding

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

What happened this week? CRISPR Crew, SynBio Infograph, Novartis Venture Fund

BioArt: Joana Ricou shows the Beautiful Similarities of the Microbiome

When Nanoparticles meet Virtual Tumours to build Oncology Platform

Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

Beyond NASH: Genfit jumps into another Critical Liver Condition

The ‘Formative Year’ of Germany’s only NASDAQ-listed Biotech

Subscribe to our newsletter to get the latest biotech news!